Replication of the DECLARE Diabetes Trial in Healthcare Claims

CompletedOBSERVATIONAL

Enrollment

49,790

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

February 18, 2021

Study Completion Date

February 18, 2021

Conditions

Diabetes

Interventions

DRUG

Dapagliflozin

Dapagliflozin dispensing claim for any dose is exposure

DRUG

DPP-4 inhibitor

DPP4 inhibitor dispensing claim for any dose is reference

Trial Locations (1)

Brigham & Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT04215523 - Replication of the DECLARE Diabetes Trial in Healthcare Claims | Biotech Hunter | Biotech Hunter